



June 13, 2024

Mark Falkowski, CEO,
Pyrexar Medical, Inc.
1825 West Research Way, Ste. E
Salt Lake City, UT 84119

Dear Petitioner:

Your petition dated 06/06/2024 was received and processed by this office on 06/13/2024 and it was assigned docket number FDA-2024-P-2846.

Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of this petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Maria Myrill
Lead Administrative Proceedings Specialist
Dockets Management Staff
FDA/Office of Operations (OO)